RCM
PRDS

Radcliffe Capital Management’s Pardes Biosciences, Inc. Common Stock PRDS Stock Holding History

Radcliffe Capital Management’s Portfolio PRDS Stock Details PRDS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-50,000
Closed -$499K – 944
2021
Q2 		$499K Hold
50,000
– – 0.02% 847
2021
Q1 		$498K Buy
+50,000
New +$517K 0.02% 643

Other funds holding PRDS

ACA
Arena Capital Advisors Los Angeles, California $208M AUM 11.42% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
JCM
JS Capital Management New York $109M AUM 34.13% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return
SRCM
Sage Rock Capital Management New York $22.3M AUM 4.09% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return

Radcliffe Capital Management's PRDS Position: Q3 2021 in Review

Radcliffe Capital Management sold out of Pardes Biosciences, Inc. Common Stock (PRDS) in Q3 2021, closing a stake of 50,000 shares — an estimated $499K sold.

Radcliffe Capital Management first reported a position in PRDS in Q1 2021 and held it in 2 quarters. The position peaked at $499K in Q2 2021. 61 funds tracked by Wall St. Rank hold PRDS as of Q3 2021.

  • Radcliffe Capital Management reported no remaining Pardes Biosciences, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
  • Radcliffe Capital Management sold 50,000 Pardes Biosciences, Inc. Common Stock shares in Q3 2021, an estimated $499K.
  • Radcliffe Capital Management first reported a position in Pardes Biosciences, Inc. Common Stock in Q1 2021 and held it in 2 quarters.
  • Radcliffe Capital Management's Pardes Biosciences, Inc. Common Stock position peaked at $499K in Q2 2021.
  • 61 funds tracked by Wall St. Rank held Pardes Biosciences, Inc. Common Stock as of Q3 2021.

Based on Radcliffe Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.